RedHill Biopharma

RDHLPhase 3

Tel-Aviv, IsraelFounded 2009redhillbio.com

RedHill Biopharma is a publicly traded, Israel-based biopharmaceutical company with a mission to improve lives through innovative medicines targeting gastrointestinal diseases, infectious diseases, and oncology. The company has built a deep pipeline of late-stage clinical candidates, with a particular strategic focus on developing oral, broad-acting antiviral therapies for pandemic preparedness and medical countermeasures. RedHill operates with commercial infrastructure in both Israel and the United States, aiming to bring novel treatments to market for conditions with high unmet need.

Market Cap

$4.5M

Founded

2009

Focus

Small Molecules

RDHL · Stock Price

USD 0.882799.12 (-99.97%)

Historical price data

AI Company Overview

Technology Platform

Focus on developing host-directed, oral, small-molecule therapies with broad-spectrum, viral mutation-resistant properties, particularly for pandemic and biodefense applications.

Pipeline Snapshot

20 drugs in pipeline, 8 in Phase 3

Drug	Indication	Stage
RHB-102 + Placebo Oral Tablet	Gastroenteritis	Phase 3
RHB-105 + Placebo	Dyspepsia	Phase 3
RHB-104 + Placebo	Crohn's Disease	Phase 3
RHB-105 + Active Comparator	Helicobacter Pylori Infection	Phase 3
RHB-204 + Placebo	Pulmonary Mycobacterium Avium Complex Infection	Phase 3

Funding History

Total raised: $135M

Debt$50MHCRMar 15, 2021

PIPE$25MUndisclosedMay 15, 2020

IPO$60MUndisclosedJan 15, 2016

Opportunities

Significant growth opportunity lies in securing government contracts for pandemic and medical countermeasure stockpiling of its late-stage, broad-spectrum oral antivirals (opaganib, RHB-107).

Further commercialization of its GI portfolio and successful development of its oncology assets present additional revenue and value drivers.

Risk Factors

Key risks include clinical trial failures in late-stage programs, regulatory setbacks, challenges in commercial execution against established competitors, and ongoing dependence on raising capital to fund operations until profitability is achieved.

Competitive Landscape

Competes with large pharma in GI and oncology, and with biodefense contractors/other biotechs in infectious diseases. Differentiation is based on novel formulations in GI and the host-directed, oral, broad-spectrum mechanism of its antiviral candidates for pandemic preparedness.